The pharmaceutical industry has become increasingly dependent on outsourcing as a means of driving both discovery and development pipelines. As the trend toward early-stage discovery being the domain of small to mid-size – and even virtual – biotech companies grows, the decision of what to outsource (and to which supplier) has become more and more critical.

Download this free research report based on a recent survey from WuXi AppTec and Informa Pharma Intelligence, which looks at the main considerations for emerging biopharma companies when choosing to partner with a CRO.